Phase 2 Endometrial Cancer Trial, Recruiting NCT06640283 Sponsor: Instituto do Cancer do Estado de São Paulo Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT06640283
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with cancer of the anal canal or cervix, confirmed by a tissue sample (biopsy).
  • People whose cancer has been found to be linked to HPV (Human Papillomavirus).
  • People whose cancer is contained within the local area — specifically, anal canal cancer at stage I to III, or cervical cancer at stage IB2 to IVA, based on standard medical staging guidelines.
  • People whose planned treatment is radiation therapy, with or without chemotherapy, as the main course of treatment.
  • People who are generally active and able to carry out daily activities with no or minimal limitations (confirm with trial site regarding how this is assessed).
  • People aged 18 or older.
  • People who are willing to sign a consent form agreeing to take part in the trial.
  • People who are HIV-positive may be considered if their immune cell count (CD4) is 200 or above.
  • People already taking part in other studies may be considered, as long as those other studies do not involve treatments for the cancer being treated in this trial.

Who may not be able to join:

  • People whose cancer has clearly spread to distant parts of the body at the time of diagnosis.
  • People whose cancer shows clear signs of getting worse on their first scan after completing radiation treatment, or who need surgery immediately after finishing their main treatment (this applies to a specific phase of the trial — confirm with trial site).
  • People who need frequent blood transfusions, such as on a weekly basis.
  • People who have another serious, uncontrolled medical condition that the treating doctor considers to be life-threatening.
  • People who have had another active invasive cancer within the past 5 years — though certain skin cancers and very early-stage cancers that have not spread may still be considered.
  • People who are pregnant.
  • People who currently have an active serious infection or related illness.
  • People with a history of autoimmune diseases.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maria DP Estevez Diz, Doctor, Oncologist

Phone: +55 11 3893-3566

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Instituto do Cancer do Estado de São Paulo
Registry
ClinicalTrials.gov
Start date
14 March 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

General Objective

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov